Severe obesity, a susceptibility factor for developing inflammatory bowel disease: results of a population-based study - Top-Institutions - MDSpire

Severe obesity, a susceptibility factor for developing inflammatory bowel disease: results of a population-based study

  • By

  • Fiorella Cañete

  • Emili Vela

  • Margalida Calafat

  • Jordi Piera

  • Míriam Mañosa

  • Eugeni Domènech

  • January 18, 2025

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Gastroenterology
    • Obesity Medicine
    • Immunology

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Gastroenterology
    • Bariatric Surgery
    • Epidemiology

  • #3

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Gastroenterology
    • Immunology
    • Epidemiology

  • #4

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Gastroenterology
    • Obesity Medicine
    • Translational Research

  • #5

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Gastroenterology
    • Obesity Research
    • Population Health

Original Source(s)

Severe obesity, a susceptibility factor for developing inflammatory bowel disease: results of a population-based study

  • by Fiorella Cañete, Emili Vela, Margalida Calafat, Jordi Piera, Míriam Mañosa, Eugeni Domènech

  • January 18, 2025

Related Content

Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation

Frontline Pharma: Sarah O’Keeffe

Ahead of HPLC 2026, Eli Lilly’s Sarah O’Keeffe reflects on leadership, collaboration, and the analytical advances helping bring increasingly complex medicines to patients

Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026